Edition:
India

Evergrande Health Industry Group Ltd (0708.HK)

0708.HK on Hong Kong Stock

4.53HKD
22 Jun 2018
Change (% chg)

HK$0.08 (+1.80%)
Prev Close
HK$4.45
Open
HK$4.45
Day's High
HK$4.59
Day's Low
HK$4.40
Volume
3,988,000
Avg. Vol
6,898,760
52-wk High
HK$4.88
52-wk Low
HK$1.47

Summary

Name Age Since Current Position

Shouming Shi

44 2018 Executive Chairman of the Board

Xiaoran Han

29 2015 Executive Director

Kar Chun Fong

41 2015 Company Secretary

Shing Yim Chau

54 2015 Non-Executive Independent Director

Jianwen Guo

39 2015 Non-Executive Independent Director

Wu Xie

50 2015 Non-Executive Independent Director

Biographies

Name Description

Shouming Shi

Mr. Shi Shouming is Executive Chairman of the Board of the company. He has more than 20 years of experience in corporate management and the management of project development and operation. He graduated from Sichuan University with a bachelor’s degree in management engineering. Prior to joining the Company, he was the president of Hengda Real Estate Group, a subsidiary of China Evergrande Group (Stock Code: 3333), the controlling shareholder of the Company. He has resigned from that position as at the date of this announcement. He served in various capacities, including the vice president, and the general manager of the corporate development centre and investment centre of Hengda Real Estate Group, and the chairman of the Hohhot company, the Hainan company, the Beijing limited company and the Sichuan company of Hengda Real Estate Group. He was appointed as the president of Hengda Real Estate Group in March 2017.

Xiaoran Han

Mr. Han Xiaoran is Executive Director of the Company. He has six year experience in investing, financing and comprehensive management. He was the assistant to general manager of the Shandong operations of Evergrande and the deputy general manager of Evergrande’s operations in the United States, and is currently the deputy general manager of Evergrande Health Industry Research Centre. Mr. Han graduated from Jilin University with a bachelor of science degree in computer science and technology.

Kar Chun Fong

Mr. Fong Kar Chun, Jimmy is Company Secretary of the Company. Mr. Fong is a member of the Law Society of Hong Kong and has been a qualified solicitor in Hong Kong since 2001.

Shing Yim Chau

Mr. Chau Shing Yim, David is Non-Executive Independent Director of the Company. He has over 22 years of experience in corporate finance, and participated in various projects ranging from initial public offerings, restructuring of PRC enterprises and cross-border and domestic takeovers. Mr. Chau is currently an independent non-executive director of Evergrande Real Estate Group Limited (Stock Code: 3333), Up Energy Development Group Limited (Stock Code: 307), Lee & Man Paper Manufacturing Limited (Stock Code: 2314), Man Wah Holdings Limited (Stock code: 1999), Richly Field China Development Limited (Stock code: 313), and Varitronix International Limited (Stock Code: 710), and the shares of all these companies are listed on the Stock Exchange. Mr. Chau was formerly a partner of Deloitte Touche Tohmatsu, heading the merger and acquisition and corporate advisory services department. He is a member of the Hong Kong Securities Institute, the Institute of Chartered Accountants of England and Wales (‘‘ICAEW’’), holding the Corporate Finance Qualification granted by ICAEW, and he is also a member of the Hong Kong Institute of Certified Public Accountants (‘‘HKICPA’’). Mr. Chau was an ex-committee member of the Disciplinary Panel of HKICPA.

Jianwen Guo

Mr. Guo Jianwen is Non-Executive Independent Director of the Company. He is currently the head and Chief Physician of the Cerebrovascular and Cardiovascular Pathology Division of the Brain Pathology Centre of Guangdong Provincial Hospital of Traditional Chinese Medicine (Guangzhou University of Chinese Medicine 2nd Affiliated Hospital), the founder of Guangzhou Wen Mai Tang Technology Company Limited, the founder and director of Guangzhou Wen Mai Tang Traditional Chinese Medicine Centre (Chain) Company Limited, the supervisor of the Strategic Development Committee of the Jiangsu Nantong Liangchun Hospital, the senior consultant of technological development at the Jiangsu Nantong Liangchun Clinical Research Institute of Traditional Chinese Medicine. He is a senior head practitioner of Traditional Chinese medicine and has level 3 surgeon qualifications in neurointervention. In July 1998, Mr. Guo received a bachelor’s degree in medicine from Beijing University of Chinese Medicine. In July 2001, he received a master’s degree in clinical internal Chinese medicine from Chengdu University of Traditional Chinese Medicine. In July 2004, he received a doctoral degree in clinical internal Chinese medicine (specializing in brain emergency diseases) from Chengdu University of Traditional Chinese Medicine.

Wu Xie

Mr. Xie Wu is Non-Executive Independent Director of the Company. He is a physician of Traditional Chinese internal medicine. He has practiced clinical Chinese medicine for 24 years, with more than 10 years experience in hemodialysis and extensive clinical experience in various sub-fields of nephrology. He worked in the kidney clinic in the People’s Hospital in Luohu, Shenzhen and engaged in medical work in Yueyang Luowang Hospital, and is currently working at the hemodialysis center of nephrology and rheumatology of Yueyang Hospital of Traditional Chinese Medicine.

Basic Compensation

Options Compensation